ECOR
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
electroCore, Inc. (ECOR) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | B- (2.9) | B (3.3) | B (3.4) | C+ (2.6) | B- (3.1) |
| 2026-11-04 | B- (3.0) | B- (2.9) | B (3.4) | A (4.2) | C+ (2.7) | B (3.2) |
| 2026-10-28 | B- (3.0) | B- (2.9) | B (3.5) | A (4.5) | C+ (2.7) | B (3.3) |
| 2026-10-21 | B- (3.0) | B- (2.9) | B (3.5) | A (4.4) | C+ (2.6) | B (3.3) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe